Skip to main content
Top
Published in: Drugs in R&D 1/2011

Open Access 01-03-2011 | Original Research Article

Comparison of Dissolution Profiles and Serum Concentrations of Two Lamotrigine Tablet Formulations

Authors: Mladena Lalic, Ana Pilipovic, Svetlana Golocorbin-Kon, Ksenija Gebauer-Bukurov, Ksenija Bozic, Momir Mikov, Dr Jelena Cvejic

Published in: Drugs in R&D | Issue 1/2011

Login to get access

Abstract

Objective: The aim of this study was to investigate the extent of variations in lamotrigine serum concentrations between two immediate-release tablet formulations. Data were compared with in vitro difference and similarity tests on dissolution profiles of the two formulations.
Methods: Dissolution characteristics of formulations A (reference) and B (test) were evaluated at three points spanning the physiologic pH range (pH 1.2, pH 4.5, pH 6.8). A model-independent approach of difference (f1) and similarity (f2) tests were applied to dissolution data. A clinical study was performed with 16 patients who were divided into two groups — one group received formulation A (n=9) and the other received formulation B (n=7). Lamotrigine steady-state concentrations were determined by high-performance liquid chromatography on a reverse-phase column.
Results: There were no statistically significant differences in lamotrigine serum concentrations between the two groups, although formulation B had slightly higher mean concentration values (formulation A: 3.97±4.1 μg/mL; formulation B: 5.78±2.7 μg/mL). Dissolution profiles of the two formulations were similar in the pH 1.2 dissolution medium; however, the dissolution profiles of formulation B were outside the dissolution limit (≥85% at 15 minutes) in the pH 4.5 and 6.8 dissolution media.
Conclusions: No significant changes in the serum concentrations of lamotrigine were seen between the two investigated formulations. There is no evidence to suggest that the differences in dissolution profiles at pH 4.5 and pH 6.8 affect the therapeutic efficacy of the formulations. It is evident that the doses of test formulation given to the patients were higher as a consequence of common assumption that generic products have a lower absorption rate, which is proven unnecessary in this study. This investigation was a pilot study and thus further investigations with a larger sample size are necessary to determine if there is a connection between dissolution profiles and the therapeutic effect of investigated formulations.
Literature
1.
go back to reference EUCARE. European white paper in epilepsy. Epilepsia 2003; 44(6): 1–88 EUCARE. European white paper in epilepsy. Epilepsia 2003; 44(6): 1–88
2.
go back to reference Besag FMC. Is generic prescribing acceptable in epilepsy? Drug Safety 2000; 23: 173–82CrossRef Besag FMC. Is generic prescribing acceptable in epilepsy? Drug Safety 2000; 23: 173–82CrossRef
3.
go back to reference Kramer G, Schneble H, Wolf P. Risks of the new “aut idem” regulations for treatment with antiepileptic drugs. Akt Neurol 2002; 29: 115–22CrossRef Kramer G, Schneble H, Wolf P. Risks of the new “aut idem” regulations for treatment with antiepileptic drugs. Akt Neurol 2002; 29: 115–22CrossRef
4.
go back to reference Jacoby A, Baker G, Steen N, et al. The clinical course of epilepsy and its psychosocial correlate: findings from a UK community study. Epilepsia 1996; 37: 148–61PubMedCrossRef Jacoby A, Baker G, Steen N, et al. The clinical course of epilepsy and its psychosocial correlate: findings from a UK community study. Epilepsia 1996; 37: 148–61PubMedCrossRef
5.
go back to reference Crawford P, Hall WW, Chappell B, et al. Generic prescribing for epilepsy: is it safe? Seizure 1996; 5: 1–5PubMedCrossRef Crawford P, Hall WW, Chappell B, et al. Generic prescribing for epilepsy: is it safe? Seizure 1996; 5: 1–5PubMedCrossRef
6.
go back to reference Anonymous. For and against generic prescribing. Drug Ther Bull 1987; 25: 93–5 Anonymous. For and against generic prescribing. Drug Ther Bull 1987; 25: 93–5
7.
go back to reference Meyer MC, Straughn AB. Biopharamaceutical factors in seizure control and drug toxicity. Am J Hosp Pharm 1993; 50 (5): S17–22PubMed Meyer MC, Straughn AB. Biopharamaceutical factors in seizure control and drug toxicity. Am J Hosp Pharm 1993; 50 (5): S17–22PubMed
8.
go back to reference Andermann F, Duh MS, Gosselin A, et al. Compulsory generic switches of antriepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 2007; 48: 464–9PubMedCrossRef Andermann F, Duh MS, Gosselin A, et al. Compulsory generic switches of antriepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 2007; 48: 464–9PubMedCrossRef
9.
go back to reference Blier P. Brand versus generic medications: the money, the patients and the research. J Psychiatry Neurosci 2003; 28: 167–8PubMed Blier P. Brand versus generic medications: the money, the patients and the research. J Psychiatry Neurosci 2003; 28: 167–8PubMed
10.
go back to reference Markus GM, McCormick J. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. Clin Ther 2007; 29: 1249–50 Markus GM, McCormick J. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. Clin Ther 2007; 29: 1249–50
11.
go back to reference Cohen AF, Land GS, Breimer DD, et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987; 42: 535–41PubMedCrossRef Cohen AF, Land GS, Breimer DD, et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987; 42: 535–41PubMedCrossRef
12.
go back to reference Levy RH, Mattson RH, Meldrum BS, et al. Antiepileptic drugs. 5th rev. ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2002 Levy RH, Mattson RH, Meldrum BS, et al. Antiepileptic drugs. 5th rev. ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2002
13.
go back to reference Physicians’ Desk Reference. Toronto (ON): Thomson PDR, 2007; 61: 1481-90 Physicians’ Desk Reference. Toronto (ON): Thomson PDR, 2007; 61: 1481-90
14.
go back to reference Sweetman S. Martindale: the complete drug reference. London: Pharmaceutical Press, 2007 Sweetman S. Martindale: the complete drug reference. London: Pharmaceutical Press, 2007
15.
go back to reference Thaddeus HG, Fiedler-Kelly J, Cox E, et al. Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. J Clin Pharmacol 1999; 39: 373–84CrossRef Thaddeus HG, Fiedler-Kelly J, Cox E, et al. Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. J Clin Pharmacol 1999; 39: 373–84CrossRef
16.
go back to reference Bialer M. Generic products of antiepileptic drugs (AEDs): is it an issue? Epilepsia 2007; 48 (10): 1825–32PubMedCrossRef Bialer M. Generic products of antiepileptic drugs (AEDs): is it an issue? Epilepsia 2007; 48 (10): 1825–32PubMedCrossRef
18.
go back to reference Wilner AN. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav 2004; 5: 995–8PubMedCrossRef Wilner AN. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav 2004; 5: 995–8PubMedCrossRef
19.
go back to reference Kramer G, Biraen A, Carreno M, et al. Current approaches to the use of generic antiepileptic drugs. Epilpsy Behav 2007; 11: 46–52CrossRef Kramer G, Biraen A, Carreno M, et al. Current approaches to the use of generic antiepileptic drugs. Epilpsy Behav 2007; 11: 46–52CrossRef
20.
go back to reference Nielsen KA, Dahl M, Tommerup E, et al. Comparative daily profile with different preparations of lamotrigine: a pilot investigation. Epilepsy Behav 2008; 13: 127–30PubMedCrossRef Nielsen KA, Dahl M, Tommerup E, et al. Comparative daily profile with different preparations of lamotrigine: a pilot investigation. Epilepsy Behav 2008; 13: 127–30PubMedCrossRef
21.
go back to reference Sripalakit P, Srichaiya A, Kandee R. Development and validation of a HPLC method for a dissolution test of lamotrigine tablets and its application to drug quality control studies. J Liquid Chromatography & Related Technologies 2008; 31: 926–39CrossRef Sripalakit P, Srichaiya A, Kandee R. Development and validation of a HPLC method for a dissolution test of lamotrigine tablets and its application to drug quality control studies. J Liquid Chromatography & Related Technologies 2008; 31: 926–39CrossRef
22.
go back to reference Patil KM, Bodhankar SL. Simultaneous determination of lamotrigine, phenobarbitone, carbamazepine and phenytoin in human serum by high-performance liquid chromatography. J Pharmaceut Biomed 2005; 39: 181–6CrossRef Patil KM, Bodhankar SL. Simultaneous determination of lamotrigine, phenobarbitone, carbamazepine and phenytoin in human serum by high-performance liquid chromatography. J Pharmaceut Biomed 2005; 39: 181–6CrossRef
23.
go back to reference United States Pharmacopoeial Convention. The United States Pharmacopoeia. 28th ed. Rockville (MD) 2005 United States Pharmacopoeial Convention. The United States Pharmacopoeia. 28th ed. Rockville (MD) 2005
24.
go back to reference Paul C, Sousa Lobo JM. Modeling and comparation of dissolution profiles. Eur J Pharm Sci 2001; 13: 123–33CrossRef Paul C, Sousa Lobo JM. Modeling and comparation of dissolution profiles. Eur J Pharm Sci 2001; 13: 123–33CrossRef
25.
go back to reference Guidance for Industry. Dissolution testing of immediate release solid oral dosage forms. Rockville (MD): U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 1997 Aug Guidance for Industry. Dissolution testing of immediate release solid oral dosage forms. Rockville (MD): U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 1997 Aug
26.
go back to reference Morris RG, Black AB, Harris AL, et al. Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of routine service. Br Clin Pharmacol 1998; 46: 547–51CrossRef Morris RG, Black AB, Harris AL, et al. Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of routine service. Br Clin Pharmacol 1998; 46: 547–51CrossRef
27.
go back to reference Lalic M, Cvejic J, Popovic J, et al. Lamotrigine and valproate pharmacokinetics interactions in epileptic patients. Eur J Drug Metab Pharmacokinet 2009; 34 (2): 93–9PubMedCrossRef Lalic M, Cvejic J, Popovic J, et al. Lamotrigine and valproate pharmacokinetics interactions in epileptic patients. Eur J Drug Metab Pharmacokinet 2009; 34 (2): 93–9PubMedCrossRef
28.
go back to reference Guberman A, Corman C. Generic substitution for brand name antiepileptic drugs: a survey. Can J Neurol Sci 2000; 27: 37–43PubMed Guberman A, Corman C. Generic substitution for brand name antiepileptic drugs: a survey. Can J Neurol Sci 2000; 27: 37–43PubMed
29.
go back to reference Souliman S, Blanquet S, Beyssac E, et al. A level A in vitro/in vivo correlation in fasted and fed states using different methods: applied to solid immediate release oral dosage form. Eur J Pharm Sci 2006; 27: 72–9PubMedCrossRef Souliman S, Blanquet S, Beyssac E, et al. A level A in vitro/in vivo correlation in fasted and fed states using different methods: applied to solid immediate release oral dosage form. Eur J Pharm Sci 2006; 27: 72–9PubMedCrossRef
30.
go back to reference Lue BM, Nielsen FS, Magnussen T, et al. Using biorelevant dissolution to obtain IVIC of solid dosage forms containing a poorly-soluble model compound. Eur J Pharm Biopharm 2008; 69: 648–57PubMedCrossRef Lue BM, Nielsen FS, Magnussen T, et al. Using biorelevant dissolution to obtain IVIC of solid dosage forms containing a poorly-soluble model compound. Eur J Pharm Biopharm 2008; 69: 648–57PubMedCrossRef
31.
go back to reference Shah HJ, Subbaiah G, Patel DM, et al. In vitro-in vivo correlation of modified release dosage form of lamotrigine. Biopharm Drug Dispos 2009; 30: 524–31PubMedCrossRef Shah HJ, Subbaiah G, Patel DM, et al. In vitro-in vivo correlation of modified release dosage form of lamotrigine. Biopharm Drug Dispos 2009; 30: 524–31PubMedCrossRef
32.
go back to reference Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 1997; 43: 457–65PubMedCrossRef Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 1997; 43: 457–65PubMedCrossRef
33.
go back to reference MPA (Läkemedelsverket) substitutable medical products. Medical Products Agency. Uppsala: Läkemedelsverket, 2006 MPA (Läkemedelsverket) substitutable medical products. Medical Products Agency. Uppsala: Läkemedelsverket, 2006
Metadata
Title
Comparison of Dissolution Profiles and Serum Concentrations of Two Lamotrigine Tablet Formulations
Authors
Mladena Lalic
Ana Pilipovic
Svetlana Golocorbin-Kon
Ksenija Gebauer-Bukurov
Ksenija Bozic
Momir Mikov
Dr Jelena Cvejic
Publication date
01-03-2011
Publisher
Springer International Publishing
Published in
Drugs in R&D / Issue 1/2011
Print ISSN: 1174-5886
Electronic ISSN: 1179-6901
DOI
https://doi.org/10.2165/11588260-000000000-00000

Other articles of this Issue 1/2011

Drugs in R&D 1/2011 Go to the issue

Correspondence

Author’s Reply